References
- Chen XW, Sun J, Zhou SF. Protein kinase inhibitors for clinical targeted cancer treatment. Clin Pharmacol Biopharmaceut 2013;2:1–2
- Dhanasekaran N, Reddy EP. Signaling by dual specificity kinases. Oncogene 1998;17:1447–55
- Paul MK, Mukhopadhyay AK. Tyrosine kinase – role and significance in cancer. Int J Med Sci 2004;1:101–15
- Giamas G, Man YL, Hirner H, et al. Kinases as targets in the treatment of solid tumors. Cell Signal 2010;22:984–1002
- Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9:28–39
- Cohen P. Protein kinases – the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002;1:309–15
- Christoffersen T, Guren TK, Spindler KG, et al. Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. Eur J Pharmacol 2009;625:6–22
- Tsai CJ, Nussinov R. The molecular basis of targeting protein kinases in cancer therapeutics. Sem Cancer Biol 2013;23:235–42
- Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene 2000;19:5548–57
- Blume-Jensen P, Hunter T. Oncogenic kinase signaling. Nature 2001;411:355–65
- El-Deeb IM, Yoo KH, Lee SH. ROS receptor tyrosine kinase: a new potential target for anticancer drugs. Med Res Rev 2011;31:794–818
- Park BS, El-Deeb IM, Yoo KH, et al. Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor. Bioorg Med Chem Lett 2009;19:4720–3
- El-Deeb IM, Park BS, Jung SJ, et al. Design, synthesis, screening, and molecular modeling study of a new series of ROS1 receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett 2009;19:5622–6
- Berger D, Dutia M, Powell D, et al. Anilinoimidazo[4,5-g]quinoline-7-carbonitriles as Src Kinase Inhibitors. Bioorg Med Chem Lett 2002;12:2761–5
- Richard DJ, Verheijen JC, Curran K, et al. Incorporation of water-solubilizing groups in pyrazolopyrimidine mTOR inhibitors: discovery of highly potent and selective analogs with improved human microsomal stability. Bioorg Med Chem Lett 2009;10:6830–5
- Reaction Biology Corporation Web Site. Available from: www.reactionbiology.com
- Awad MM, Katayama R, McTigue M, et al. Acquired resistance to crizotinib from a mutation in CD74–ROS1. N Engl J Med 2013;368:2395–401